Humoral, T-cell and B-cell immune responses to seasonal influenza vaccine in solid organ transplant recipients receiving anti-T cell therapies.

Détails

ID Serval
serval:BIB_131AECC2C5F7
Type
Article: article d'un périodique ou d'un magazine.
Collection
Publications
Titre
Humoral, T-cell and B-cell immune responses to seasonal influenza vaccine in solid organ transplant recipients receiving anti-T cell therapies.
Périodique
Vaccine
Auteur(s)
Héquet D., Pascual M., Lartey S., Pathirana R.D., Bredholt G., Hoschler K., Hullin R., Meylan P., Cox R.J., Manuel O.
ISSN
1873-2518 (Electronic)
ISSN-L
0264-410X
Statut éditorial
Publié
Date de publication
30/06/2016
Peer-reviewed
Oui
Volume
34
Numéro
31
Pages
3576-3583
Langue
anglais
Notes
Publication types: Journal Article
Publication Status: ppublish
Résumé
We analyzed the impact of the anti-T-cell agents basiliximab and antithymocyte globulins (ATG) on antibody and cell-mediated immune responses after influenza vaccination in solid-organ transplant recipients.
71 kidney and heart transplant recipients (basiliximab [n=43] and ATG [n=28]) received the trivalent influenza vaccine. Antibody responses were measured at baseline and 6 weeks post-vaccination by hemagglutination inhibition assay; T-cell responses were measured by IFN-γ ELISpot assays and intracellular cytokine staining (ICS); and influenza-specific memory B-cell (MBC) responses were evaluated using ELISpot.
Median time of vaccination from transplantation was 29 months (IQR 8-73). Post-vaccination seroconversion rates were 26.8% for H1N1, 34.1% for H3N2 and 4.9% for influenza B in the basiliximab group and 35.7% for H1N1, 42.9% for H3N2 and 14.3% for influenza B in the ATG group (p=0.44, p=0.61, and p=0.21, respectively). The number of influenza-specific IFN-γ-producing cells increased significantly after vaccination (from 35 to 67.5 SFC/10(6) PBMC, p=0.0007), but no differences between treatment groups were observed (p=0.88). Median number of IgG-MBC did not increase after vaccination (H1N1, p=0.94; H3N2 p=0.34; B, p=0.79), irrespective of the type of anti-T-cell therapy.
After influenza vaccination, a significant increase in antibody and T-cell immune responses but not in MBC responses was observed in transplant recipients. Immune responses were not significantly different between groups that received basiliximab or ATG.

Mots-clé
Adult, Antibodies, Monoclonal/therapeutic use, Antilymphocyte Serum/therapeutic use, B-Lymphocytes/immunology, Female, Heart Transplantation, Hemagglutination Inhibition Tests, Humans, Immunity, Cellular, Immunity, Humoral, Immunologic Memory, Immunosuppressive Agents/therapeutic use, Influenza A Virus, H1N1 Subtype, Influenza A Virus, H3N2 Subtype, Influenza Vaccines/therapeutic use, Influenza, Human/prevention & control, Kidney Transplantation, Male, Middle Aged, Prospective Studies, Recombinant Fusion Proteins/therapeutic use, T-Lymphocytes/immunology, Transplant Recipients, Biological agents, Immunogenicity, Induction, Prevention, Viral infection
Pubmed
Web of science
Open Access
Oui
Création de la notice
06/06/2016 16:14
Dernière modification de la notice
20/08/2019 12:41
Données d'usage